Recent and Upcoming Drug Therapies for Pediatric Heart Failure
暂无分享,去创建一个
[1] Jose H. Flores-Arredondo,et al. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. , 2021, Journal of the American College of Cardiology.
[2] A. Bogers,et al. Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome , 2021, ESC heart failure.
[3] J. Januzzi,et al. Understanding the Mechanistic Benefit of Heart Failure Drugs Matters. , 2020, Journal of the American College of Cardiology.
[4] P. Ponikowski,et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.
[5] Akshay S. Desai,et al. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. , 2020, JACC. Heart failure.
[6] E. Braunwald,et al. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. , 2020, JACC. Heart failure.
[7] Akshay S. Desai,et al. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. , 2020, JACC. Heart failure.
[8] M. Vaduganathan,et al. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. , 2020, International journal of cardiology.
[9] Yinan Li,et al. Effect of Prophylactic Levosimendan on All-Cause Mortality in Pediatric Patients Undergoing Cardiac Surgery—An Updated Systematic Review and Meta-Analysis , 2020, Frontiers in Pediatrics.
[10] E. Braunwald,et al. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. , 2020, JACC. Heart failure.
[11] S. Solomon,et al. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. , 2020, JACC. Heart failure.
[12] S. Solomon,et al. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. , 2020, Circulation. Heart failure.
[13] M. Gold,et al. Left Bundle Branch Pacing: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[14] A. Mebazaa,et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper , 2019, Critical Care.
[15] S. Heymans,et al. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes , 2019, JACC. Basic to translational science.
[16] B. Meiser,et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric heart transplantation report - 2019; Focus theme: Donor and recipient size match. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[17] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[18] P. Ponikowski,et al. Effects of Serelaxin in Patients with Acute Heart Failure. , 2019, The New England journal of medicine.
[19] S. Colan,et al. Cardiac Biomarkers in Pediatric Cardiomyopathy: Study Design and Recruitment Results from the Pediatric Cardiomyopathy Registry. , 2019, Progress in pediatric cardiology.
[20] Akshay S. Desai,et al. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. , 2019, Circulation.
[21] L. Allen,et al. Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[22] E. Bertini,et al. Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy. , 2019, International journal of cardiology.
[23] W. Chung,et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. , 2018, Circulation.
[24] B. Das. Current State of Pediatric Heart Failure , 2018, Children.
[25] S. Apostolopoulou,et al. Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation , 2018, Pediatric Cardiology.
[26] M. Burch,et al. Systematic Literature Review on the Incidence and Prevalence of Heart Failure in Children and Adolescents , 2017, Pediatric Cardiology.
[27] M. Burch,et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA‐HF study) , 2017, American heart journal.
[28] P. Ponikowski,et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. , 2017, JACC. Heart failure.
[29] P. Kantor,et al. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. , 2017, Journal of the American College of Cardiology.
[30] K. Anstrom,et al. Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.
[31] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[32] J. Wilkinson,et al. 965Increased heart rate is independently associated with worse survival in pediatric patients with dilated cardiomyopathy: a multicenter study from the pediatric cardiomyopathy registry , 2017 .
[33] P. Ponikowski,et al. Rationale for and design of the TRUE‐AHF trial: the effects of ularitide on the short‐term clinical course and long‐term mortality of patients with acute heart failure , 2017, European journal of heart failure.
[34] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.
[35] M. Nieminen,et al. The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure , 2017, European heart journal supplements : journal of the European Society of Cardiology.
[36] P. Rautiainen,et al. The Hemodynamic Effects and Safety of Repetitive Levosimendan Infusions on Children With Dilated Cardiomyopathy , 2017, World journal for pediatric & congenital heart surgery.
[37] Piotr Ponikowski,et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial , 2016, The Lancet.
[38] F. Fruhwald,et al. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations , 2016, Expert review of cardiovascular therapy.
[39] A. Cohen-Solal,et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion Nieminen, , 2022 .
[40] N. Jayaprasad,et al. Heart Failure in Children , 2016, Heart views : the official journal of the Gulf Heart Association.
[41] B. McCrindle,et al. Angiotensin‐Converting Enzyme Inhibitor Initiation and Dose Uptitration in Children With Cardiovascular Disease: A Retrospective Review of Standard Clinical Practice and a Prospective Randomized Clinical Trial , 2016, Journal of the American Heart Association.
[42] S. Colan,et al. Utilization and Safety of Long-Term Carvedilol in Pediatric Dilated Cardiomyopathy: A Multicenter Study from the Pediatric Cardiomyopathy Registry , 2016 .
[43] Piotr Ponikowski,et al. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. , 2016, Journal of the American College of Cardiology.
[44] M. Naim,et al. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure , 2016, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[45] R. Starling,et al. Duration of Heart Failure Is an Important Predictor of Outcomes After Mechanical Circulatory Support , 2015, Circulation. Heart failure.
[46] D. Hsu,et al. Serial Measurement of Amino-Terminal Pro-B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Outcome in Children With Primary Myocardial Dysfunction and Acute Decompensated Heart Failure , 2015, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[47] J. Thambo,et al. Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy. , 2015, Archives of cardiovascular diseases.
[48] K. Krobert,et al. The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium , 2015, PloS one.
[49] P. Ponikowski,et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies , 2015, European heart journal.
[50] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.
[51] S. Colan,et al. Abstract 16801: Improved Transplant-Free Survival of Children With Dilated Cardiomyopathy: Analysis of Two Decades From the Pediatric Cardiomyopathy Registry , 2014 .
[52] J. Towbin,et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[53] R. Shaddy,et al. Heart failure in children: etiology and treatment. , 2014, The Journal of pediatrics.
[54] D. Leosco,et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. , 2014, JACC. Heart failure.
[55] L. Lund,et al. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry , 2014, European journal of heart failure.
[56] P. Kantor,et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. , 2013, The Canadian journal of cardiology.
[57] K. Swedberg,et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. , 2013, European heart journal.
[58] B. Massie,et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.
[59] P. Ponikowski,et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.
[60] Piotr Ponikowski,et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.
[61] P. Cogo,et al. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial , 2012, Intensive Care Medicine.
[62] P. Suominen. Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure , 2011, BMC anesthesiology.
[63] S. Bohora,et al. Reversal of Tachycardiomyopathy Due to Left Atrial Tachycardia by Ivabradine , 2011, Journal of cardiovascular electrophysiology.
[64] B. McCrindle,et al. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure. , 2011, The American journal of cardiology.
[65] F. Shann,et al. Rotating inotrope therapy in a pediatric population with decompensated heart failure , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[66] F. Cabañas,et al. Acute Effects of Levosimendan on Cerebral and Systemic Perfusion and Oxygenation in Newborns: An Observational Study , 2010, Neonatology.
[67] G. Felker,et al. A global rank end point for clinical trials in acute heart failure. , 2010, Circulation. Heart failure.
[68] D. Hsu,et al. BNP Levels Predict Outcome in Pediatric Heart Failure Patients: Post Hoc Analysis of the Pediatric Carvedilol Trial , 2010, Circulation. Heart failure.
[69] Whitney W. Smith,et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. , 2010, ACS medicinal chemistry letters.
[70] R. Shaddy,et al. Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations , 2010, Pediatrics.
[71] L. Mertens,et al. Clinical practice , 2010, European Journal of Pediatrics.
[72] Gail D Pearson,et al. Heart failure in children: part II: diagnosis, treatment, and future directions. , 2009, Circulation. Heart failure.
[73] Sanjiv J. Shah,et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORI , 2009, American heart journal.
[74] Y. Okutani,et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[75] G. Filippatos,et al. Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure (HORIZON-HF) Trial , 2008, American journal of therapeutics.
[76] F. Schmidt. Meta-Analysis , 2008 .
[77] C. Wren,et al. Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations , 2007, Archives of Disease in Childhood Fetal and Neonatal Edition.
[78] P. Seferovic,et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. , 2006, European heart journal.
[79] S. Colan,et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. , 2006, JAMA.
[80] S. Colan,et al. Factors Associated With Establishing a Causal Diagnosis for Children With Cardiomyopathy , 2006, Pediatrics.
[81] J. Towbin,et al. B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Events in Pediatric Outpatients With Chronic Left Ventricular Systolic Dysfunction , 2006, Circulation.
[82] L. Shekerdemian,et al. Early experience with Levosimendan in children with ventricular dysfunction* , 2006, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[83] I. Édes,et al. The levosimendan metabolite OR‐1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles , 2006, British journal of pharmacology.
[84] W. Colucci,et al. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.
[85] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[86] John B Carlin,et al. The epidemiology of childhood cardiomyopathy in Australia. , 2003, The New England journal of medicine.
[87] E John Orav,et al. The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.
[88] R. Califf,et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.
[89] A. Zangrillo,et al. A systematic review on levosimendan in paediatric patients. , 2015, Current vascular pharmacology.
[90] J. Price,et al. National prescribing trends for heart failure medications in children. , 2015, Congenital heart disease.
[91] S. Paridon,et al. Pediatric versus adult cardiomyopathy and heart failure-related hospitalizations: a value-based analysis. , 2015, Journal of cardiac failure.
[92] M. Nieminen,et al. Levosimendan: current data, clinical use and future development , 2013, Heart, lung and vessels.
[93] V. Vukomanovic,et al. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children]. , 2011, Vojnosanitetski pregled.
[94] T. Elbert,et al. Etiology and Treatment , 2010 .
[95] Gail D Pearson,et al. Heart failure in children: part I: history, etiology, and pathophysiology. , 2009, Circulation. Heart failure.
[96] S. Hampson. Randomised, placebo-controlled trial , 2002 .
[97] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[98] D. Nelson,et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics. , 2002, American heart journal.
[99] S. Kobourov,et al. 1 Executive summary , 1998 .
[100] H. Haikala,et al. Mechanisms of action of calcium-sensitizing drugs. , 1995, Journal of cardiovascular pharmacology.
[101] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[102] Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.
[103] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.